<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181961</url>
  </required_header>
  <id_info>
    <org_study_id>2004-P-001269</org_study_id>
    <nct_id>NCT00181961</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Maca Root to Treat Antidepressant-Induced Sexual Dysfunction</brief_title>
  <official_title>A Dose-Finding Study of the Tolerability and Efficacy of Maca Root in Patients With Antidepressant-Induced Sexual Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the dose of Maca Root effective for the treatment
      of antidepressant-induced sexual dysfunction in patients with DSM-IV defined Major Depressive
      Disorder. We propose to carry out a dose-finding pilot study to determine the minimum
      effective dose of Maca Root. We hypothesize that patients who receive Maca Root will
      experience alleviation of their sexual dysfunction, and this effect will be more pronounced
      in those who receive higher doses of maca root.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether Maca Root is effective for the treatment of
      antidepressant-induced sexual dysfunction, and to further determine whether higher doses of
      Maca Root powder would be more effective than lower doses in reducing the symptoms of
      antidepressant-induced sexual dysfunction. An additional aim of the study is to document the
      safety and tolerability of Maca Root, which could be particularly helpful in treating
      antidepressant-induced sexual dysfunction in elderly and cardiac-impaired populations taking
      oral nitrates who may not be eligible for treatment with the current oral phosphodiesterase
      inhibitors.

      Subjects will be randomized into two arms of 10 for this 12-week study. The study will be
      double blind with regard to doses received. Ten subjects will receive 1500mg/day of maca for
      the 12-week period and the other 10 subjects will receive 3000mg/day of maca per day for the
      12-week study period. Patients will be seen every other week. There is no placebo arm.

      At the final study visit, week 12, subjects will be evaluated to see if their sexual function
      has returned.

      After careful review of the literature we have found that there are very few studies that
      have evaluated Maca Root in humans. However the one very relevant study completed by Gonzalez
      and colleagues looked at doses of 1500 and 3000mg in men and found there were increased
      sexual interests on both doses. Thus, since this is a dose-finding study we believe this dose
      is an appropriate place to begin.

      Hypotheses A:

      The response rate will be higher for the high-dose maca group compared to the low-dose group;
      and this response will be comparable to the 50-85% reported with sildenafil.

      Hypothesis B:

      There will be a statistically significant difference in the magnitude of response between the
      two testing conditions, as measured by a decrease in baseline sexual dysfunction scores. The
      reduction in sexual dysfunction scores will be greater in the high-dose maca group than in
      the low-dose maca group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Massachusetts General Hospital Sexual Dysfunction Inventory Scores</measure>
    <time_frame>baseline to endpoint (8 weeks)</time_frame>
    <description>Full title: Massachusetts General Hospital Sexual Dysfunction Inventory Minimum score for Men: 5 Minimum score for Women: 4 Maximum score for Men: 30 Maximum score for Women: 24
*One item on the measure is for men only
A score of a 5 (4 for women) indicates improvement in sexual function. A score of 10 (8 for women) indicates no change. A score higher than 10 (8 for women) indicates a level of sexual dysfunction.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Depression</condition>
  <condition>Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Maca Root 1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving 1500mg of maca root</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maca Root 3000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving 3000mg of maca root</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maca Root</intervention_name>
    <arm_group_label>Maca Root 1500mg</arm_group_label>
    <arm_group_label>Maca Root 3000mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have been taking an SSRI, venlafaxine, nefazodone, or tri/hetero cyclic
             antidepressant for treatment of depression for at least 8 weeks, are currently at a
             stable dose of the antidepressant for at least 4 weeks, and have been consistently
             experiencing arousal dysfunction (inability to attain or maintain an adequate
             lubrication/swelling response of sexual excitement until completion of sexual
             activity) or orgasmic dysfunction (delayed orgasm/anorgasmia following a normal sexual
             excitement phase) that interferes with sexual function for at least 4 weeks.

        Subjects must currently be euthymic (HAM-D&lt; 10) and without significant anxiety symptoms
        (HAM-A&lt;10). These scales will rely on retrospective reporting from the participant.

        Subjects must have had no sexual dysfunction prior to taking an antidepressant and there
        must be a clear temporal relationship between the sexual dysfunction and the antidepressant
        treatment. Sexual dysfunction occurring as a symptom of the depressive disorder for which
        the antidepressant treatment was initiated is not considered to be a pre-existing condition
        under this definition.

          -  Subjects must meet at least one of the following criteria:

               -  Inability to have an orgasm (anorgasmia), according to patient opinion

               -  Clinically significant orgasm delay with masturbation or intercourse that
                  according to patient opinion represents a meaningful delay and interferes with
                  subject's sexual function compared with the subject's usual time to achieve
                  orgasm in response to sexual stimulation prior to antidepressant medication

               -  Inability to attain or maintain until completion of sexual activity an adequate
                  an erection or lubrication swelling response of sexual excitement that, according
                  to patient opinion, interferes with subject's sexual function, compared to prior
                  to antidepressant medication.

               -  Decreased libido according to patient opinion (and verified by objective
                  measurements)

          -  Subjects must experience at least one of the above criterion items with distress and
             or disability.

          -  Subjects must be having or had been having some form of regular sexual activity
             (masturbation, oral sex, intercourse) at least twice monthly prior to the
             antidepressant treatment and are willing to continue efforts at sexual activity at
             least once weekly for the duration of the study

          -  Subjects must be in good general physical health

        Exclusion Criteria:

          -  Primary or prior diagnosis of a sexual disorder (other than the side effect of the
             antidepressant drug or symptom of major depression)

          -  Sexual dysfunction secondary to general underlying medical condition

          -  Any uncontrolled psychiatric disorder

          -  Alcohol or substance abuse or dependence within the past six months

          -  Recent major relationship changes, disruption, or turmoil ongoing or anticipated which
             are unrelated to their sexual dysfunction

          -  Hamilton Depression and/or Anxiety Scale score (either) &gt;10

          -  Blood pressure outside the range of 90/50 - 170/100

          -  Use of investigational drugs within prior 3 months or during study.

          -  Current use of other drugs for antidepressant induced sexual dysfunction or other
             therapies or medications to treat sexual dysfunction

          -  Hormone replacement therapy, unless patient has been on stable dose of hormone therapy
             for at least 3 months prior to the antidepressant treatment and had no sexual
             dysfunction while on the same hormone therapy regimen, and there is no change in the
             hormone replacement therapy during the study

          -  Pregnancy, lactating, or planning to become pregnant during the study

          -  Child bearing potential subjects unwilling and/or not prepared and/or who are judged
             unreliable to use an acceptable and verifiable form of contraception during the study

          -  Any clinically significant abnormality of the screening physical examination

          -  History of elevated PSA levels that are greater than 0.2 (as defined by MGH labs)

          -  History of prostate or other hormonal cancers

          -  Prior use of maca for at least two weeks

          -  Infection of the urogenital tract that may make sexual activity painful or difficult

          -  Subjects whose sexual partners are suffering from and/or receiving treatment for
             sexual dysfunction

          -  Receiving psychosexual or other therapy for sexual dysfunction and not willing to
             discontinue that treatment at screening

          -  Subjects not attempting some form of regular sexual activity at least twice monthly
             and at least once weekly during study visit intervals for the duration of the entire
             study

          -  Changes in antidepressant agent and/or dose of prescribed antidepressant agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina M Dording, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>December 3, 2018</results_first_submitted>
  <results_first_submitted_qc>August 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Christina M. Dording, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>antidepressant-induced sexual dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maca Root 1500mg</title>
          <description>Patients receiving 1500mg of maca root
Maca Root</description>
        </group>
        <group group_id="P2">
          <title>Maca Root 3000mg</title>
          <description>Patients receiving 3000mg of maca root
Maca Root</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Maca Root 1500mg</title>
          <description>Patients receiving 1500mg of maca root
Maca Root</description>
        </group>
        <group group_id="B2">
          <title>Maca Root 3000mg</title>
          <description>Patients receiving 3000mg of maca root
Maca Root</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="12"/>
                    <measurement group_id="B2" value="34" spread="15"/>
                    <measurement group_id="B3" value="36" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Massachusetts General Hospital Sexual Dysfunction Inventory Scores</title>
        <description>Full title: Massachusetts General Hospital Sexual Dysfunction Inventory Minimum score for Men: 5 Minimum score for Women: 4 Maximum score for Men: 30 Maximum score for Women: 24
*One item on the measure is for men only
A score of a 5 (4 for women) indicates improvement in sexual function. A score of 10 (8 for women) indicates no change. A score higher than 10 (8 for women) indicates a level of sexual dysfunction.</description>
        <time_frame>baseline to endpoint (8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maca Root 1500mg</title>
            <description>Patients receiving 1500mg of maca root
Maca Root</description>
          </group>
          <group group_id="O2">
            <title>Maca Root 3000mg</title>
            <description>Patients receiving 3000mg of maca root
Maca Root</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Massachusetts General Hospital Sexual Dysfunction Inventory Scores</title>
          <description>Full title: Massachusetts General Hospital Sexual Dysfunction Inventory Minimum score for Men: 5 Minimum score for Women: 4 Maximum score for Men: 30 Maximum score for Women: 24
*One item on the measure is for men only
A score of a 5 (4 for women) indicates improvement in sexual function. A score of 10 (8 for women) indicates no change. A score higher than 10 (8 for women) indicates a level of sexual dysfunction.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".249" spread="2.39"/>
                    <measurement group_id="O2" value=".017" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.016</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Maca Root 1500mg</title>
          <description>Patients receiving 1500mg of maca root
Maca Root</description>
        </group>
        <group group_id="E2">
          <title>Maca Root 3000mg</title>
          <description>Patients receiving 3000mg of maca root
Maca Root</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Upset</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Sleep issues</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thicker Menstrual Discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Fibromyalgia Exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christina Dording</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177249457</phone>
      <email>cdording@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

